Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Foundations Investment Advisors LLC

Key Points

• Foundations Investment Advisors LLC increased its holdings in Gilead Sciences, Inc. by 3.9%, owning 65,558 shares valued at approximately $7.35 million.
• Insider trading was reported, including sales by CFO Andrew D. Dickinson and insider Johanna Mercier, with total insider sales in the past three months amounting to 72,000 shares worth nearly $7.84 million.
• Research analysts have diverse sentiments towards Gilead Sciences, with 15 ratings as "buy" and an average price target set at $112.36.

Foundations Investment Advisors LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 65,558 shares of the biopharmaceutical company's stock after acquiring an additional 2,476 shares during the period. Foundations Investment Advisors LLC's holdings in Gilead Sciences were worth $7,346,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of GILD. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences during the 1st quarter worth about $25,000. Goodman Advisory Group LLC bought a new position in Gilead Sciences during the 1st quarter worth about $29,000. Annis Gardner Whiting Capital Advisors LLC lifted its position in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 216 shares during the last quarter. Core Alternative Capital lifted its position in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares during the last quarter. Finally, IMA Advisory Services Inc. purchased a new stake in shares of Gilead Sciences during the first quarter valued at about $39,000. Institutional investors own 83.67% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on GILD. Oppenheimer decreased their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research report on Friday, July 25th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Finally, Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Eight analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $112.36.

Gilead Sciences Trading Up 0.8%

Shares of NASDAQ GILD traded up $0.88 during trading on Friday, hitting $113.17. 2,618,569 shares of the company were exchanged, compared to its average volume of 8,410,775. Gilead Sciences, Inc. has a 12-month low of $72.43 and a 12-month high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The company has a fifty day moving average price of $110.40 and a 200-day moving average price of $106.55. The firm has a market capitalization of $140.78 billion, a PE ratio of 23.78, a P/E/G ratio of 0.72 and a beta of 0.29.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider directly owned 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $277,575.00. Following the sale, the chief financial officer directly owned 162,610 shares of the company's stock, valued at $18,054,588.30. The trade was a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $8,984,175 in the last quarter. 0.27% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.